FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced results from its pilot clinical study evaluating the safety and clinical utility of Augment Injectable Bone Graft (AIBG, formerly known as GEM OS2) for the treatment of closed distal radius (wrist) fractures. In the randomized, controlled study evaluating distal radius fractures treated with external fixation versus external fixation combined with minimally invasive injection of AIBG, patients treated with Augment Injectable demonstrated earlier bone formation as measured by CT scans. Additionally, all AIBG patients had a 100% bone fill at six months compared to 82% of the control patients.
